Lung cancer is the most common cause of cancer-related mortality worldwide, and adenocarcinoma is currently the most common histologic subtype. 1 Conventionally, adenocarcinomas have been grouped into 3 distinct grades including well, moderately, and poorly differentiated. In addition, several distinct patterns of growth have been reported, including mucinous, papillary, micropapillary, hepatoid, and signet-ring cell among others. 2-13 However, primary oncocytic adenocarcinomas of the lung have not been addressed as a specific clinicopathologic entity. Oncocytic neoplasms are well recognized and accepted in other organ systems, including the salivary gland, thyroid, and kidney, where these tumors appear to be more common. Needless to say, owing to the unusual occurrence and lack of proper recognition, the presence of an oncocytic adenocarcinoma in the lung will inevitably lead to the possibility of metastatic disease to the lung.
Lung cancer is the most common cause of cancer-related mortality worldwide, and adenocarcinoma is currently the most common histologic subtype. 1 Conventionally, adenocarcinomas have been grouped into 3 distinct grades including well, moderately, and poorly differentiated. In addition, several distinct patterns of growth have been reported, including mucinous, papillary, micropapillary, hepatoid, and signet-ring cell among others. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, primary oncocytic adenocarcinomas of the lung have not been addressed as a specific clinicopathologic entity. Oncocytic neoplasms are well recognized and accepted in other organ systems, including the salivary gland, thyroid, and kidney, where these tumors appear to be more common. Needless to say, owing to the unusual occurrence and lack of proper recognition, the presence of an oncocytic adenocarcinoma in the lung will inevitably lead to the possibility of metastatic disease to the lung.
Herein, we describe 16 primary oncocytic adenocarcinomas of the lung, which we consider represent a specific clinicopathologic entity and one that needs to be recognized and not mistaken for metastatic disease to the lung.
3 to 22 H&E-stained glass slides of tumor. Detailed clinical and pathologic information was available in all cases, including demographic data, smoking history, clinical and surgical staging, overall survival, and recurrence data. Paraffin blocks were available in 14 cases to perform immunohistochemical studies and molecular analysis.
All tumors were evaluated following the subclassification proposed by the World Health Organization, 14 and, in addition, the percentage of necrosis and mitotic index were recorded in each case. The main criterion for inclusion in this study was more than 50% oncocytic differentiation in any of the recognized growth patterns. For immunohistochemical studies, antibodies for cytokeratin 7 Molecular studies included EGFR mutation analysis of exons 18 through 21 and KRAS mutation analysis of exons 1 and 2 with polymerase chain reaction (PCR) amplification using intron-based primers, as previously described, using approximately 200 microdissected cells for each PCR amplification test. 15, 16 All PCR products were directly sequenced using the Applied Biosystems PRISM dye terminator cycle sequencing method (Applied Biosystems, Foster City, CA). All sequence variants were confirmed by independent PCR amplification from at least 2 independent microdissections and DNA extraction and sequenced in both directions, as previously reported. 15, 16 After each of the aforementioned studies was performed, the 16 cases were further evaluated with the respective results. All cases selected on histologic evaluation were reevaluated after immunohistochemical and molecular biologic studies were completed.
Results

Clinical Features
The most important clinical features are given in ❚Table 1❚. The patients included 11 women and 5 men between the ages of 47 and 81 years (median, 75 years; mean, 71 years). Of the 16 patients, 14 (88%) are tobacco users (10 former users and 4 current users), and 2 patients never used tobacco. Common symptoms for all patients included cough, shortness of breath, and chest pain. None of the patients had a history of malignancy elsewhere. Radiologically, all the patients were 
Macroscopic Features
Of the tumors, 15 tumors were in the periphery of the lung parenchyma and 1 in the pulmonary hilum. In 1 case, there were 2 distinct contiguous tumor nodules, whereas in the remaining cases, there was a single pulmonary mass. The left lung was the site of 9 tumors, and 7 were located in the right lung. The tumors were described as well circumscribed, light tan, with and without areas of necrosis and/or hemorrhage. The tumors varied in size from 1.2 to 4.9 cm in greatest diameter.
Histologic Features
The 16 oncocytic adenocarcinomas were grouped in the conventional 3-tier category, showing 5 well-differentiated, 7 moderately differentiated, and 4 poorly differentiated adenocarcinomas. Four distinct growth patterns were observed in these adenocarcinomas: acinar, solid, papillary, and bronchioloalveolar in different percentages in a given tumor ❚Table 2❚, ❚Image 1❚, ❚Image 2❚, ❚Image 3❚, ❚Image 4❚, ❚Image 5❚, ❚Image 6❚, and ❚Image 7❚. A mixture of growth patterns was observed in 12 cases, whereas only 4 tumors showed a single growth pattern. However, regardless of the growth pattern, the salient feature of all of these tumors was that they were composed of medium-sized cells with ample eosinophilic "oncocytic" cytoplasm, round nuclei, and conspicuous nucleoli. In some areas, larger polygonal cells resembling "oncoblasts" were also present. In tumors with a papillary pattern, the growth pattern resembled that described in the oncocytic variant of papillary carcinoma of the thyroid, ie, the presence of a prominent papillary configuration with anastomosing cords of neoplastic cells with little intervening stroma, whereas in tumors with a solid pattern, there were sheets of neoplastic cells without any particular arrangement. It is interesting that in some tumors, a prominent bronchioloalveolar pattern was also identified. Areas of necrosis were observed in 7 cases that ranged from approximately 10% to 50%, whereas mitotic figures ranged from 1 to 8 mitotic figures per 10 high-power fields.
Immunohistochemical Features
Immunohistochemical studies were performed in 14 cases. All tumors studied showed positive staining for cytokeratin 7 and for TTF-1 ❚Image 8A❚, whereas thyroglobulin was negative in all cases. Cytokeratin 20 was focally positive in 2 cases. Mitochondrial antigen showed variable staining patterns; in 13 cases, the staining pattern was intense 2+ and 3+ ❚Image 8B❚, whereas in 1 case, the staining pattern was 1+ and focal. In addition, other stains for the possibility of Clara cell differentiation were performed showing DC-LAMP with focal, positive staining in 2 cases and 2 additional cases with diffuse strong cytoplasmic staining, whereas surfactant protein A (PE-10) showed focal positive staining in 4 cases and strong positive cytoplasmic staining in only 1 case. In only 1 case did we observe the presence of DC-LAMP and PE-10+ staining ❚Table 3❚. 
Molecular Analysis
Mutation analyses for EGFR
Follow-up Information
Clinical follow-up data for at last 24 months were available for all patients (Table 1) . Recurrence-free survival at 2 years was 75% (12 patients), and overall survival was 88% (14 patients). Overall, 5 patients had recurrence (recurrence time ranged from 3.6 to 32 months). Two patients died of the tumor (~7 and 47 months), 2 died of unrelated conditions, and 1 died of unknown cause (~45 months) without evidence of recurrence.
Discussion
The existence of oncocytic features in primary tumors of the lung is well known, and in the majority of cases, such features have been reported in neuroendocrine tumors, including neuroendocrine carcinomas (carcinoid tumors) and primary paragangliomas of the lung. In addition, similar oncocytic features have also been described in salivary gland-type tumors, ie, acinic cell carcinoma and primary oncocytomas of the lung. [17] [18] [19] [20] [21] On the other hand, it is also well known that the lungs are a common place for metastatic neoplasms, ie, those originating in the thyroid, salivary gland, and kidney. Therefore, careful clinical and pathologic correlations must be undertaken to code a tumor as of lung origin.
It is interesting that although these oncocytic features are well recognized, they have been rarely mentioned or addressed in the literature as a specific clinicopathologic entity. We have been able to document 16 such cases that, in our experience, represent approximately 3% of all primary adenocarcinomas of the lung. Similar to what occurs in other oncocytic neoplasms, the cells of oncocytic adenocarcinomas of the lung also are filled with mitochondria. However, the mitochondrial amount in cells varies from type to type and under different physiologic conditions in the same type of cells. Also, the occurrence of these oncocytic changes has been stated to be secondary to cell aging, degenerative process, and inflammation. 22, 23 In addition, the role of mitochondria in neoplasms is not clear, but it is has been proposed that an increase in number is secondary to a compensatory mechanism caused by defective organelles as a consequence of alteration in the mitochondrial carcinoma would express positive staining for neuroendocrine markers. On the other hand, the oncocytic variant of acinic cell carcinoma may be more problematic because acinic cell carcinoma not only may show an acinar growth pattern but also may show positive staining for cytokeratin and TTF-1. However, in cases of acinic cell carcinoma, the tumor may also show more conventional areas, which on histochemical stains for periodic acid-Schiff will show extensive deposition of intracellular glycogen. Primary oncocytoma of the lung may pose a much more difficult problem in separating it from oncocytic adenocarcinoma. However, the presence of mixed patterns of growth such as acinar, papillary, and/or solid patterns in the same tumor would be unusual for oncocytoma. In addition, in our cases, we were able to observe that many cases also showed a bronchioloalveolar growth pattern, which would be unusual in primary oncocytomas of the lung. Needless to say, primary oncocytomas of the lung are exceedingly rare and have been reported only in rare instances. 19, 20 The cases herein presented are, in our experience, an unusual growth pattern of primary adenocarcinoma of the lung. The recognition of the oncocytic variant of adenocarcinoma of the lung is important to avoid confusion with metastatic neoplasms to the lung and other primary lung neoplasms. These adenocarcinomas, just like other types, may show similar immunohistochemical features and molecular mutations. Recognition is important to properly classify these tumors and for the proper treatment of the patients.
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DNA or in the DNA encoding for mitochondrial proteins. 24 Mitochondria can accumulate only in tumor cells that are not actively dividing, thus, the rationale for labeling oncocytic tumors as having low malignant potential. 25, 26 One other explanation for the oncocytic changes in a given tumor may be related to radiation and/or chemotherapy because those procedures may increase the number of mitochondria in cells. 27 The presence of an oncocytic growth pattern in pulmonary adenocarcinomas is clearly not a product of radiation or chemotherapy, because none of our patients was treated before surgical excision of the tumor was performed. In addition, we do not consider oncocytic adenocarcinoma of the lung as a low-malignant-potential neoplasm because in some of our cases, the patients died as a consequence of their tumor. We further stress that the behavior of these tumors is more closely linked to the clinical and pathologic staging of the tumor at the time of diagnosis.
One interesting feature that we observed was that oncocytic changes in adenocarcinomas of the lung were more likely to occur in tumors smaller than 5 cm in diameter, rather than in larger tumors. Even though we investigated the possibility of pneumocyte type II and/or Clara cell origin in these tumors, immunohistochemical studies did not show strong evidence of that possibility because only a minority of cases showed positive staining, and in most of the cases, the positivity was only focal and weak. Our study also showed that the molecular results in these cases closely mirror those in the general population and that the finding of oncocytic changes is not by any means a feature that can be correlated with specific molecular mutations.
More important, we consider that the different growth pattern observed in oncocytic adenocarcinomas of the lung may be mimicked by metastatic tumors to the lung, and, as such, the differential diagnosis of these tumors should include metastasis from thyroid, salivary gland, and renal tumors. In this setting, the use of immunohistochemical studies, ie, cytokeratin 7 and TTF-1, should be of great aid because oncocytic adenocarcinomas of the lung, as evidenced by our experience, would express positive staining for those markers. Nevertheless, in cases in which there is a history of a neoplasm of any of those organ systems (kidney, thyroid, or salivary gland), a complete panel of immunohistochemical studies needs to be undertaken before labeling a case as metastatic disease.
In addition, other primary tumors of the lung should also be considered in the differential diagnosis, including primary paraganglioma, oncocytic neuroendocrine carcinoma, and the oncocytic variant of acinic cell carcinoma of the lung. In the first 2 tumoral conditions, the use of neuroendocrine markers, essentially chromogranin, synaptophysin, and/ or CD56, should aid in leading toward a more appropriate interpretation because paraganglioma and neuroendocrine
